{"meta":{"query_hash":"c98e8d888c40","filters":{"venue":"Future Rare Diseases"},"cohort_total":19,"direct_labels_cover":0,"predictions_cover":19,"exported":19,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/c98e8d888c40","api":"https://metacan.xera.ac/api/v1/cohort?venue=Future+Rare+Diseases"},"results":[{"id":"W3128891271","doi":"10.2217/frd-2020-0006","title":"Transfusion of Modified Blood Components for the Treatment of Autoimmune Hemolytic Anemia: A Network Meta-Analysis","year":2021,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Blood groups and transfusion","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; McMaster University","funders":"","keywords":"Medicine; Incidence (geometry); Autoimmune hemolytic anemia; Adverse effect; Anemia; Randomized controlled trial; Internal medicine; Immunology; Hemoglobin; Hemolytic anemia; Meta-analysis","score_opus":0.041170669707332005,"score_gpt":0.2736758022095728,"score_spread":0.2325051325022408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128891271","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06587329,0.93018496,0.0010236186,0.0005023906,0.00037167882,0.00029878708,0.00092017185,0.00005182593,0.0007731823],"genre_scores_gemma":[0.8017018,0.19276568,0.0019465139,0.001174178,0.00040233487,0.0005146168,0.000997019,0.000033210523,0.00046470913],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99552864,0.0025850416,0.0007764671,0.00060293666,0.00035434106,0.00015247229],"domain_scores_gemma":[0.9924211,0.0053652404,0.0014690456,0.00024705584,0.0003373171,0.0001603391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00616535,0.0013073145,0.0074754246,0.0013446598,0.00034018603,0.0017343953,0.0010589099,0.001329251,0.0028926411],"category_scores_gemma":[0.011675808,0.0005815424,0.0152039565,0.0019170948,0.00037452937,0.0008072678,0.00061067904,0.001518255,0.00016273052],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041186124,0.00012910774,0.012719778,0.091650605,0.8318623,0.00011181913,0.000044018198,0.0009722278,0.0006535469,0.00015256427,0.00084203715,0.019675914],"study_design_scores_gemma":[0.007620108,0.0012177688,0.0114502655,0.0043193684,0.97302204,0.00008184723,0.000023756358,0.00052487035,0.00019535347,0.00018038592,0.0013460087,0.00001814445],"about_ca_topic_score_codex":0.0029564295,"about_ca_topic_score_gemma":0.0050365794,"teacher_disagreement_score":0.0074754246,"about_ca_system_score_codex":0.0010117467,"about_ca_system_score_gemma":0.00083983236,"threshold_uncertainty_score":0.032605886},"labels":[],"label_agreement":null},{"id":"W4317212031","doi":"10.2217/frd-2022-0015","title":"The Effects of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva: A Plain Language Summary","year":2023,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Heterotopic Ossification and Related Conditions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; University Health Network","funders":"Daiichi Sankyo Europe; UCB Pharma; Incyte; BioCryst; Mead Johnson Nutrition; International Fibrodysplasia Ossificans Progressiva Association; Ultragenyx Pharmaceutical; Ipsen; Regeneron Pharmaceuticals; Pfizer","keywords":"Fibrodysplasia ossificans progressiva; Clinical trial; Medicine; Heterotopic bone; Myositis ossificans; Physical therapy; Bone formation; Dentistry; Surgery; Heterotopic ossification; Internal medicine","score_opus":0.002490181814365724,"score_gpt":0.22673687399539838,"score_spread":0.22424669218103266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317212031","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007069143,0.93563724,0.00044778618,0.035710998,0.0067335074,0.0007852498,0.0029911061,0.00007336423,0.010551581],"genre_scores_gemma":[0.056639876,0.8283737,0.0029364794,0.07710445,0.018943941,0.0020445182,0.0037484963,0.00006900348,0.010139567],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987999,0.00048609718,0.0003836766,0.0000699239,0.00019409826,0.00006635703],"domain_scores_gemma":[0.9953453,0.0022350596,0.0014292763,0.00008219796,0.0007173733,0.00019074854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025406217,0.0006363431,0.002556851,0.00070544024,0.0003066343,0.0019082687,0.00095853786,0.0018674975,0.011388274],"category_scores_gemma":[0.0056322063,0.00024627816,0.0025548416,0.0008860792,0.00043884324,0.001496776,0.00042184666,0.002686576,0.002203759],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021662958,0.0006285372,0.0020637487,0.1127798,0.0018867413,0.0008164208,0.00024820524,0.00044885266,0.0023048036,0.0021293508,0.22004396,0.63498664],"study_design_scores_gemma":[0.03264777,0.022843162,0.02171145,0.10900212,0.009409442,0.0037957248,0.00082261465,0.0006966744,0.0020372425,0.003986293,0.79278356,0.00026389948],"about_ca_topic_score_codex":0.00096467626,"about_ca_topic_score_gemma":0.0022251848,"teacher_disagreement_score":0.011388274,"about_ca_system_score_codex":0.00084533356,"about_ca_system_score_gemma":0.0014148194,"threshold_uncertainty_score":0.03809756},"labels":[],"label_agreement":null},{"id":"W4388536081","doi":"10.2217/frd-2023-0013","title":"Plain language summary of a study looking at whether genetic testing can help doctors diagnose the severity of mucopolysaccharidosis type I (MPS I)","year":2023,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Mucopolysaccharidosis type I; Enzyme replacement therapy; Phenotype; Missense mutation; Genotype; Gene; Genetics; Mucopolysaccharidosis I; Disease; Genotype-phenotype distinction; Enzyme; Biology; Medicine; Biochemistry; Internal medicine","score_opus":0.020261194488716258,"score_gpt":0.300552782468921,"score_spread":0.2802915879802047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388536081","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011638879,0.031904686,0.0030154581,0.2451658,0.054933768,0.0033740704,0.50534236,0.0012256299,0.14339937],"genre_scores_gemma":[0.099757314,0.05955775,0.011082821,0.41949433,0.059539374,0.01765108,0.18296164,0.0019501814,0.14800547],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99338937,0.0026471878,0.002048538,0.0005849775,0.0010076899,0.00032227213],"domain_scores_gemma":[0.9448716,0.03198762,0.0057358067,0.0013327072,0.014113973,0.00195824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036962142,0.0009048394,0.0018036925,0.0025572304,0.0012634047,0.002340344,0.0011451114,0.0027221309,0.17797038],"category_scores_gemma":[0.0734186,0.0003734088,0.00139357,0.004307103,0.0007009853,0.0027160845,0.0012449446,0.0022284607,0.046784528],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039637374,0.00003927717,0.0028864262,0.004485478,0.000056274985,0.00031312084,0.00017662367,0.000036738216,0.000094786286,0.00056550815,0.9764716,0.01447774],"study_design_scores_gemma":[0.0010334569,0.00045461114,0.038710687,0.02300724,0.00027887497,0.0017368208,0.0025533875,0.00019523551,0.00027551348,0.002287275,0.9293187,0.00014813775],"about_ca_topic_score_codex":0.013275518,"about_ca_topic_score_gemma":0.010194167,"teacher_disagreement_score":0.17797038,"about_ca_system_score_codex":0.0019370137,"about_ca_system_score_gemma":0.0040345946,"threshold_uncertainty_score":0.59537023},"labels":[],"label_agreement":null},{"id":"W4390113708","doi":"10.2217/frd-2023-0022","title":"Garadacimab for the prevention of hereditary angioedema attacks: a plain language summary of the VANGUARD study","year":2023,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Alberta; Ottawa Allergy Research Corporation; University of Ottawa","funders":"","keywords":"Hereditary angioedema; Vanguard; Placebo; Medicine; C1-inhibitor; Angioedema; Surgery; Internal medicine; Dermatology; Alternative medicine; Pathology","score_opus":0.015851182321688622,"score_gpt":0.29905527407922994,"score_spread":0.2832040917575413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390113708","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005030886,0.9119073,0.0010592239,0.043716185,0.013200036,0.0021019056,0.0055896975,0.00010874826,0.017286094],"genre_scores_gemma":[0.030244296,0.8442525,0.0045474777,0.07547713,0.022148553,0.0037258102,0.006847692,0.00019044073,0.012566141],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946142,0.002742306,0.0011838371,0.00028814384,0.0009768561,0.00019462383],"domain_scores_gemma":[0.98896384,0.0062860497,0.0018307933,0.0003799917,0.0019106537,0.00062865263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012367244,0.0009701756,0.0031935864,0.001202953,0.00034617604,0.0035561826,0.0012585213,0.0022844155,0.010325301],"category_scores_gemma":[0.015276952,0.00048086987,0.0039197635,0.0018468106,0.00044756496,0.0016484682,0.0008859851,0.0031703855,0.0025500003],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029022882,0.000590115,0.0019487257,0.09194201,0.0060624233,0.0003442173,0.00026069308,0.00043701843,0.0016161106,0.004563651,0.25255245,0.61065966],"study_design_scores_gemma":[0.041804,0.010304549,0.012533156,0.09619051,0.015826602,0.0006869208,0.00024894736,0.00036700885,0.0010594352,0.003888102,0.8168866,0.00020417792],"about_ca_topic_score_codex":0.002072118,"about_ca_topic_score_gemma":0.0021127216,"teacher_disagreement_score":0.012367244,"about_ca_system_score_codex":0.0011357886,"about_ca_system_score_gemma":0.0024623394,"threshold_uncertainty_score":0.06540507},"labels":[],"label_agreement":null},{"id":"W4391262940","doi":"10.2217/frd-2023-0024","title":"Plain language summary of efanesoctocog alfa for patients with severe hemophilia A","year":2024,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Clotting factor; Prophylactic treatment; Clinical research; Pediatrics; Surgery; Internal medicine","score_opus":0.006988405016050799,"score_gpt":0.2737567799168182,"score_spread":0.2667683749007674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391262940","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031653019,0.5021462,0.0020635687,0.23861216,0.095745936,0.0014929862,0.028086854,0.00097167474,0.12771538],"genre_scores_gemma":[0.019982908,0.47303188,0.0040916805,0.2735148,0.11707685,0.0024039645,0.021758394,0.00041903098,0.08772052],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987967,0.00042128534,0.00037862346,0.00007081082,0.0002628649,0.00006969226],"domain_scores_gemma":[0.9924269,0.0035941633,0.0013630592,0.00010031747,0.001998977,0.0005166297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013391696,0.0007279221,0.0018412197,0.0012624484,0.00043079848,0.0016400674,0.00095118844,0.0018951866,0.06186657],"category_scores_gemma":[0.009919391,0.00032451755,0.0009973632,0.0012331054,0.00024166626,0.0012756287,0.0005384707,0.0022818432,0.017479567],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046554228,0.0000530391,0.00015780822,0.005189195,0.000045193417,0.00010903071,0.000024690278,0.00007330622,0.00019492439,0.00030117205,0.9091684,0.084217645],"study_design_scores_gemma":[0.00048664372,0.00058384496,0.0026458097,0.0073326696,0.00015708311,0.0005521527,0.000058563473,0.00007057175,0.00014855547,0.00034448988,0.98759043,0.000029120649],"about_ca_topic_score_codex":0.0023936955,"about_ca_topic_score_gemma":0.0030129005,"teacher_disagreement_score":0.06186657,"about_ca_system_score_codex":0.000978625,"about_ca_system_score_gemma":0.0015789188,"threshold_uncertainty_score":0.20696425},"labels":[],"label_agreement":null},{"id":"W4394716792","doi":"10.2217/frd-2023-0028","title":"The effects of garetosmab in people with fibrodysplasia ossificans progressiva (FOP): A plain language summary of the LUMINA-1 study","year":2024,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Heterotopic Ossification and Related Conditions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Fibrodysplasia ossificans progressiva; Medicine; Plain language; Anatomy; Linguistics; Heterotopic ossification","score_opus":0.0026192150206411787,"score_gpt":0.24449630671473851,"score_spread":0.24187709169409732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394716792","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04471548,0.8746553,0.00064753566,0.046047132,0.008050784,0.0029734303,0.008461544,0.00013075584,0.014318075],"genre_scores_gemma":[0.20006773,0.67760605,0.0047322474,0.07553872,0.01885068,0.00568655,0.00658562,0.0001109621,0.01082152],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996412,0.0019931293,0.0008199704,0.00014999967,0.00048910675,0.0001358536],"domain_scores_gemma":[0.9907329,0.0052833813,0.002001697,0.00017859449,0.0012580674,0.00054532674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066740983,0.0007536996,0.0030176712,0.0009905957,0.0005675112,0.0021319806,0.0007312546,0.0023911758,0.0077499654],"category_scores_gemma":[0.011756799,0.000503678,0.004306585,0.00089894346,0.00042950912,0.0012751494,0.00066191284,0.0027421843,0.0013055097],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09721092,0.0035426656,0.00968698,0.14197658,0.011309562,0.0007271789,0.0012017204,0.00039042436,0.0023141499,0.001423559,0.16513056,0.56508565],"study_design_scores_gemma":[0.17236646,0.073662914,0.08056378,0.13122298,0.046325576,0.0020336378,0.0024550776,0.0005777422,0.0022414061,0.0026309413,0.48538512,0.00053434353],"about_ca_topic_score_codex":0.0018359823,"about_ca_topic_score_gemma":0.0034407175,"teacher_disagreement_score":0.0077499654,"about_ca_system_score_codex":0.0009168255,"about_ca_system_score_gemma":0.0014536163,"threshold_uncertainty_score":0.03529644},"labels":[],"label_agreement":null},{"id":"W4401784358","doi":"10.1080/23995270.2024.2380247","title":"A plain language summary of the NefIgArd trial: Nefecon for the treatment of patients with immunoglobulin A nephropathy","year":2024,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"AstraZeneca; Omeros Corporation; Alexion Pharmaceuticals; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Antibody; Immunology","score_opus":0.0056869594446195175,"score_gpt":0.24344805028455876,"score_spread":0.23776109083993924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401784358","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034095163,0.26824948,0.004176592,0.36472186,0.19135381,0.005574204,0.101227805,0.0010780898,0.06020861],"genre_scores_gemma":[0.017376773,0.21074745,0.0052136187,0.4446921,0.19408278,0.0092388885,0.048318338,0.0006240227,0.0697061],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953591,0.0023361286,0.0008615481,0.0002774109,0.000863221,0.00030251406],"domain_scores_gemma":[0.97742325,0.013479148,0.0030685698,0.0005280277,0.004173203,0.0013277818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008041783,0.0020106838,0.0040890328,0.0016130967,0.00064848975,0.005202589,0.0018885245,0.005825671,0.043393996],"category_scores_gemma":[0.029441226,0.0007778699,0.0048930105,0.0022730022,0.00048312364,0.0024083927,0.00066846726,0.006974709,0.012838153],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005270952,0.00009701289,0.0002883977,0.01236777,0.00090445153,0.00012147724,0.000034002023,0.00027751422,0.0002674446,0.0010525474,0.92827094,0.051047508],"study_design_scores_gemma":[0.023956256,0.0030024573,0.0064928946,0.024362212,0.0040704203,0.00039714616,0.0000994983,0.0005455232,0.0005429188,0.0047989106,0.9314984,0.00023336933],"about_ca_topic_score_codex":0.0030106152,"about_ca_topic_score_gemma":0.0033062526,"teacher_disagreement_score":0.043393996,"about_ca_system_score_codex":0.0017764269,"about_ca_system_score_gemma":0.0026718786,"threshold_uncertainty_score":0.14516741},"labels":[],"label_agreement":null},{"id":"W4401925418","doi":"10.1080/23995270.2024.2383163","title":"Plain Language Summary: Looking at treatment outcomes in people with Fabry disease who started agalsidase beta before the age of 30 years","year":2024,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Gastroenterology","funders":"","keywords":"Fabry disease; Medicine; Pediatrics; BETA (programming language); Disease; Internal medicine; Computer science","score_opus":0.007470405384718379,"score_gpt":0.2732195483789067,"score_spread":0.26574914299418834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401925418","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07239692,0.027259592,0.0011530863,0.16783546,0.015018396,0.0008418298,0.671077,0.0005106253,0.04390712],"genre_scores_gemma":[0.38135222,0.030426089,0.0044316715,0.18929097,0.021845512,0.008657413,0.29879946,0.00063578726,0.06456089],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9976775,0.0006946611,0.0007614597,0.00021276862,0.00038161557,0.00027196785],"domain_scores_gemma":[0.9791997,0.008892247,0.00542621,0.00044296068,0.004586861,0.0014519925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022440345,0.00048039178,0.001057885,0.0019787776,0.00055000524,0.0014809346,0.0009367495,0.0017626499,0.07832222],"category_scores_gemma":[0.03364188,0.00020399122,0.0017138256,0.0032501116,0.0002860626,0.002013812,0.0008110157,0.0014280303,0.012258637],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011221089,0.000111136134,0.047064025,0.0069675623,0.00038191743,0.00032596858,0.0003950458,0.00014393612,0.00010101667,0.00051514694,0.9100355,0.03283671],"study_design_scores_gemma":[0.0023699943,0.0016607067,0.57752925,0.018157844,0.0014101958,0.0019261577,0.005186201,0.00044983783,0.0004311789,0.0023863623,0.38820866,0.0002836053],"about_ca_topic_score_codex":0.007691563,"about_ca_topic_score_gemma":0.006849913,"teacher_disagreement_score":0.07832222,"about_ca_system_score_codex":0.0011440156,"about_ca_system_score_gemma":0.0019977621,"threshold_uncertainty_score":0.2620139},"labels":[],"label_agreement":null},{"id":"W4406721598","doi":"10.1080/23995270.2024.2444861","title":"The effects of elafibranor in people with primary biliary cholangitis: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nutrition Society; Canadian Paediatric Society; Canadian Cardiovascular Society; University of Calgary","funders":"Ipsen; Astellas Pharma; Fonds Wetenschappelijk Onderzoek; Boston Scientific Corporation; Gilead Sciences; GlaxoSmithKline; U.S. Department of Justice; AstraZeneca; Vlaamse regering; Dr. Falk Pharma; Pfizer; Novo Nordisk","keywords":"Plain language; Medicine; Primary (astronomy); General surgery; Internal medicine; Geography; Linguistics; Physics; Astrophysics; Philosophy","score_opus":0.0014578343983965684,"score_gpt":0.20842116826401139,"score_spread":0.20696333386561483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406721598","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001815845,0.7706167,0.00044950415,0.1782221,0.032059655,0.00044181076,0.0030231762,0.00008215321,0.013289112],"genre_scores_gemma":[0.013132211,0.7032242,0.0016898637,0.20172688,0.060912233,0.0010014402,0.002538596,0.000079854304,0.015694698],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967547,0.0013418108,0.0010237327,0.00016227784,0.00056082173,0.00015662915],"domain_scores_gemma":[0.9731337,0.016885595,0.003495795,0.00027807307,0.005585305,0.0006215952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00475397,0.0008580237,0.002297666,0.0014974202,0.00061680726,0.0032979664,0.0011037434,0.0031723857,0.018421963],"category_scores_gemma":[0.022086691,0.00042139593,0.0019118103,0.0016029082,0.0006880445,0.0026102406,0.0008655657,0.004095438,0.0057698204],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013916726,0.00015266128,0.0009239875,0.032061987,0.00026373452,0.00035009472,0.00029914378,0.00012316731,0.00033934435,0.001517837,0.7515424,0.21103397],"study_design_scores_gemma":[0.00073307724,0.001199709,0.0068826876,0.054317974,0.00062698487,0.00095061556,0.00057984324,0.00011803109,0.0002930095,0.0017399886,0.932475,0.00008322577],"about_ca_topic_score_codex":0.0031771075,"about_ca_topic_score_gemma":0.003465931,"teacher_disagreement_score":0.018421963,"about_ca_system_score_codex":0.0017304338,"about_ca_system_score_gemma":0.002474169,"threshold_uncertainty_score":0.061627626},"labels":[],"label_agreement":null},{"id":"W4407406073","doi":"10.1080/23995270.2025.2466383","title":"Letter in reply: orphan drugs approved in Canada: availability and additional therapeutic value","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Wilfrid Laurier University; Arthur B. McDonald-Canadian Astroparticle Physics Research Institute; Fraser Institute","funders":"","keywords":"Orphan drug; Value (mathematics); Medicine; Mathematics; Biology; Bioinformatics; Statistics","score_opus":0.013255557436094852,"score_gpt":0.22773559034760632,"score_spread":0.21448003291151146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407406073","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015348996,0.0006350816,0.000040027728,0.9847541,0.013463662,0.000007877215,0.00015387661,0.00002120129,0.0007706575],"genre_scores_gemma":[0.0017872414,0.00064329524,0.00011902183,0.98213124,0.012020722,0.000013807716,0.000044518918,0.00002251348,0.0032177237],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970914,0.00045612888,0.00037688043,0.00046257192,0.0010948763,0.0005181361],"domain_scores_gemma":[0.9817887,0.006691954,0.00085744134,0.00029983564,0.008070994,0.0022910852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030298952,0.00070126995,0.0018609707,0.0010822625,0.0041457987,0.0037536426,0.0025011862,0.037411585,0.010603219],"category_scores_gemma":[0.033556476,0.0007143799,0.0011543141,0.0013312047,0.0029465186,0.0029522227,0.001172584,0.03390074,0.005600885],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002116117,0.000004073101,0.0001953144,0.000020113332,0.000006141126,0.00014284697,0.000028679404,0.000013719698,0.00003213761,0.0004100346,0.99786633,0.0012594442],"study_design_scores_gemma":[0.00009065657,0.00002936588,0.0018069173,0.00030397717,0.000047916154,0.0013280615,0.00049554976,0.00027827633,0.00030062173,0.0031707531,0.992015,0.0001329051],"about_ca_topic_score_codex":0.13436335,"about_ca_topic_score_gemma":0.15876701,"teacher_disagreement_score":0.86563665,"about_ca_system_score_codex":0.011203443,"about_ca_system_score_gemma":0.01941563,"threshold_uncertainty_score":0.26716256},"labels":[],"label_agreement":null},{"id":"W4407710006","doi":"10.1080/23995270.2025.2466380","title":"Orphan drugs approved in Canada: availability and additional therapeutic value","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Orphan drug; Value (mathematics); Medicine; Business; Pharmacology; Mathematics; Statistics; Biology; Bioinformatics","score_opus":0.01286622521603255,"score_gpt":0.2277308317862886,"score_spread":0.21486460657025605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407710006","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032709553,0.018577548,0.00052445696,0.94513124,0.011116354,0.000015836866,0.0035347615,0.000023779168,0.017805066],"genre_scores_gemma":[0.21928917,0.06892092,0.0026438928,0.63224775,0.060041785,0.000041954452,0.0027650911,0.00015367054,0.013895845],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9756291,0.0028548173,0.0019027143,0.0014240855,0.016000196,0.0021890847],"domain_scores_gemma":[0.85207003,0.06655039,0.01168034,0.0025148687,0.062137596,0.0050467923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010691125,0.00045772435,0.0011936101,0.0041594347,0.003802922,0.008049319,0.0026408841,0.005930594,0.008810005],"category_scores_gemma":[0.10180257,0.00044088817,0.0009906966,0.0073058964,0.005434608,0.0038176551,0.0017503677,0.009934861,0.0009761848],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014278984,0.000014053137,0.0099628065,0.0003755602,0.00011372414,0.00043587852,0.0004075474,0.00033886966,0.000067875226,0.02786437,0.9232686,0.037007976],"study_design_scores_gemma":[0.000103040526,0.000033301672,0.02844431,0.0028010856,0.00026310762,0.0010888341,0.0017339116,0.0023252838,0.00044598637,0.028768841,0.933755,0.00023740545],"about_ca_topic_score_codex":0.88906664,"about_ca_topic_score_gemma":0.9242728,"teacher_disagreement_score":0.11093336,"about_ca_system_score_codex":0.05125535,"about_ca_system_score_gemma":0.09325688,"threshold_uncertainty_score":0.3718853},"labels":[],"label_agreement":null},{"id":"W4408500388","doi":"10.1080/23995270.2025.2466921","title":"Plain language summary of the outcomes from the first Rare Bone Disease Summit: current challenges and priority actions","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Global Affairs Canada","funders":"","keywords":"Summit; Current (fluid); Medicine; Disease; Intensive care medicine; Geography; Engineering; Internal medicine; Cartography","score_opus":0.009285446319931756,"score_gpt":0.25035602122044986,"score_spread":0.24107057490051811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408500388","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010799965,0.014086142,0.0028732172,0.47392857,0.23026505,0.0025946018,0.10683093,0.003970136,0.16437139],"genre_scores_gemma":[0.01177477,0.035961173,0.006612954,0.25821128,0.117271625,0.011938717,0.1373132,0.0029236493,0.41799268],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99275947,0.0017927764,0.0011164995,0.000384125,0.0029570924,0.0009899868],"domain_scores_gemma":[0.92838866,0.01356599,0.0038308634,0.0013234247,0.0454006,0.00749048],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008496929,0.0012552728,0.0019937255,0.0035299608,0.002470695,0.009205433,0.003040343,0.0054714535,0.35388526],"category_scores_gemma":[0.07861501,0.00061769935,0.0022364575,0.0031183641,0.0008011166,0.006055992,0.00548204,0.006506134,0.19560726],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023747954,0.0000083115965,0.000058002024,0.00019444159,0.0000018667245,0.0000113826845,0.00001161711,0.000010479722,0.0000066486045,0.00008634442,0.9905558,0.00903148],"study_design_scores_gemma":[0.000087718436,0.000047974878,0.0014912339,0.002359702,0.000015866715,0.000059101738,0.00025946676,0.00004481629,0.00004507721,0.000554072,0.99500173,0.000033373828],"about_ca_topic_score_codex":0.011655697,"about_ca_topic_score_gemma":0.014740194,"teacher_disagreement_score":0.35388526,"about_ca_system_score_codex":0.0042834054,"about_ca_system_score_gemma":0.011968195,"threshold_uncertainty_score":0.9216043},"labels":[],"label_agreement":null},{"id":"W4412069038","doi":"10.1080/23995270.2025.2515006","title":"Plain language summary: Patient journey and treatment patterns in progressive pulmonary fibrosis","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Boehringer Ingelheim","keywords":"Pulmonary fibrosis; Medicine; Field (mathematics); Fibrosis; Intensive care medicine; Pathology; Mathematics","score_opus":0.004801572897415728,"score_gpt":0.2532780850455136,"score_spread":0.24847651214809785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412069038","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20059882,0.12508233,0.0036003413,0.51614094,0.022661319,0.0006056662,0.062249776,0.0007129587,0.06834789],"genre_scores_gemma":[0.6625223,0.14212249,0.0056702443,0.096140444,0.020636493,0.0012299395,0.035605155,0.00046347186,0.035609305],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9961591,0.0019458113,0.0009033851,0.00017622304,0.0005539742,0.0002615756],"domain_scores_gemma":[0.97610873,0.010042715,0.005289527,0.00036354008,0.0064239358,0.0017715805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027401233,0.00035673028,0.0006809073,0.0022363276,0.0008605332,0.0030159226,0.0006864857,0.0011686211,0.025436113],"category_scores_gemma":[0.037356697,0.00018779152,0.0005240983,0.0024190017,0.00047903508,0.0038477383,0.0012807931,0.0014573879,0.0047830176],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032459915,0.00008603942,0.048166547,0.004499834,0.00008613457,0.0011889031,0.005834903,0.00026795286,0.00026213264,0.0010622784,0.80812544,0.13009515],"study_design_scores_gemma":[0.00013094473,0.00093486934,0.18426111,0.014071063,0.00018304403,0.0075782007,0.034673814,0.00059307454,0.0005274647,0.0019849478,0.7548178,0.00024372015],"about_ca_topic_score_codex":0.0038946967,"about_ca_topic_score_gemma":0.004308888,"teacher_disagreement_score":0.025436113,"about_ca_system_score_codex":0.0016575562,"about_ca_system_score_gemma":0.002229606,"threshold_uncertainty_score":0.08509225},"labels":[],"label_agreement":null},{"id":"W4412676182","doi":"10.1080/23995270.2025.2535273","title":"A plain language summary of the phase 1/2 study of AAV5-hRKp.RPGR (botaretigene sparoparvovec) in people with RPGR-associated X-linked retinitis pigmentosa","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"Johnson and Johnson; Moorfields Eye Hospital NHS Foundation Trust; National Institute for Health and Care Research","keywords":"Retinitis pigmentosa; Phase (matter); Medicine; Physics; Ophthalmology","score_opus":0.0033371297559092344,"score_gpt":0.23963795153892645,"score_spread":0.2363008217830172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412676182","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018857611,0.20048311,0.012720739,0.202371,0.06818182,0.070467405,0.2475458,0.0021902462,0.1771823],"genre_scores_gemma":[0.06489857,0.1853235,0.025588369,0.28160617,0.03674272,0.08600239,0.06793655,0.0013745292,0.2505272],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963606,0.001914462,0.0007569966,0.00022592623,0.0005820152,0.00016011357],"domain_scores_gemma":[0.9871727,0.006271883,0.0019933535,0.00033330263,0.0033531133,0.00087558076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006921269,0.0012654684,0.0020779506,0.0009250887,0.00076015934,0.0024441725,0.0011364337,0.0027431,0.12695612],"category_scores_gemma":[0.018757835,0.00064234715,0.0025091555,0.0007696273,0.0003726848,0.0013117677,0.00063104555,0.0026489848,0.02200722],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016513474,0.0008074342,0.0008327027,0.021526031,0.0005903322,0.00027204852,0.0001250102,0.00022916278,0.0019628203,0.0010582777,0.84545195,0.110630766],"study_design_scores_gemma":[0.022246934,0.015061654,0.006234549,0.020405505,0.0013851883,0.00050995644,0.00019979668,0.00020916938,0.0012386076,0.0016766432,0.9307178,0.00011417951],"about_ca_topic_score_codex":0.003043487,"about_ca_topic_score_gemma":0.004464489,"teacher_disagreement_score":0.12695612,"about_ca_system_score_codex":0.0013692434,"about_ca_system_score_gemma":0.002860991,"threshold_uncertainty_score":0.4247105},"labels":[],"label_agreement":null},{"id":"W4413087173","doi":"10.1080/23995270.2025.2532358","title":"How I treat Rett syndrome with trofinetide: changes in dosing frequency and administration with rice cereal","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Genetics and Neurodevelopmental Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"ACADIA Pharmaceuticals","keywords":"Rett syndrome; Dosing; Administration (probate law); Medicine; Pharmacology; Biology; Biochemistry","score_opus":0.0037080078145349036,"score_gpt":0.20301450507727434,"score_spread":0.19930649726273944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413087173","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3266819,0.10378878,0.070923276,0.3532287,0.018739264,0.0021328146,0.00093367056,0.0045474386,0.11902407],"genre_scores_gemma":[0.6329631,0.064004324,0.15693702,0.10795205,0.0086174635,0.0015759851,0.00045992312,0.0005631561,0.026926877],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9993807,0.00021498174,0.00007295479,0.00008912968,0.00017275028,0.000069443595],"domain_scores_gemma":[0.9993795,0.00021762685,0.00016929847,0.00004611501,0.000064812666,0.00012263267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012161325,0.00041962208,0.0004347223,0.0003955831,0.00053942617,0.00092277117,0.00050499785,0.0016809425,0.003918224],"category_scores_gemma":[0.0044172104,0.000195401,0.00077939837,0.00017226281,0.00080056477,0.0015273948,0.00046494708,0.0025508858,0.0020285307],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001997483,0.001889604,0.012393538,0.0014428037,0.00032912518,0.003927106,0.0012815892,0.0009215776,0.022767425,0.004916742,0.097746484,0.8503865],"study_design_scores_gemma":[0.004034028,0.016197365,0.04308355,0.0048291543,0.0011038395,0.041083016,0.0031919582,0.004103599,0.04563674,0.023955753,0.8123093,0.00047160787],"about_ca_topic_score_codex":0.0011104014,"about_ca_topic_score_gemma":0.0021750706,"teacher_disagreement_score":0.003918224,"about_ca_system_score_codex":0.0003851211,"about_ca_system_score_gemma":0.0005204491,"threshold_uncertainty_score":0.013107777},"labels":[],"label_agreement":null},{"id":"W4415687071","doi":"10.1080/23995270.2025.2570636","title":"Plain Language Summary: kidney function and severe clinical events in people with Fabry disease who receive agalsidase beta","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Global Affairs Canada","funders":"Sanofi","keywords":"Fabry disease; Renal function; BETA (programming language); Kidney disease; Disease","score_opus":0.008033434704794291,"score_gpt":0.2978692758426545,"score_spread":0.2898358411378602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415687071","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008494967,0.041988555,0.0012305141,0.588567,0.17334269,0.00082694483,0.14198965,0.0007648161,0.042794775],"genre_scores_gemma":[0.061241824,0.057265542,0.003234259,0.51025444,0.16565427,0.004119182,0.07852731,0.0007953921,0.1189078],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977825,0.00087998365,0.00057499076,0.00018228234,0.00042738684,0.00015292494],"domain_scores_gemma":[0.96683717,0.015620986,0.0042846566,0.00063047133,0.010869715,0.0017570332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002369403,0.00095779705,0.0018897059,0.0020576017,0.0008602746,0.003029122,0.0016987791,0.0026977025,0.14126657],"category_scores_gemma":[0.044277098,0.0003765187,0.0012783373,0.0024511756,0.00059030944,0.0027475057,0.0010421551,0.0033305853,0.03253382],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013315406,0.000018798597,0.00087895006,0.0006362726,0.000017109413,0.000054433163,0.000032583663,0.000017861561,0.000022306647,0.0001072752,0.99248946,0.005591835],"study_design_scores_gemma":[0.0007705091,0.00046363648,0.040634483,0.010803974,0.00016106911,0.0012002395,0.0012437581,0.00030611551,0.00021836777,0.0013031242,0.9427544,0.00014024375],"about_ca_topic_score_codex":0.0075544696,"about_ca_topic_score_gemma":0.0060070427,"teacher_disagreement_score":0.14126657,"about_ca_system_score_codex":0.0015629795,"about_ca_system_score_gemma":0.0019957693,"threshold_uncertainty_score":0.47258377},"labels":[],"label_agreement":null},{"id":"W4417216476","doi":"10.1080/23995270.2025.2597031","title":"Real-world use of trofinetide: a survey of practices from prescribers at Rett syndrome centers of excellence in the United States","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Genetics and Neurodevelopmental Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Excellence; Rett syndrome; MEDLINE; CLARITY","score_opus":0.02088355461246003,"score_gpt":0.27030777140471646,"score_spread":0.24942421679225643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417216476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969422,0.00042744863,0.00011637229,0.0011062153,0.000006603838,0.00003241601,0.00035009827,0.0000055401906,0.0010130535],"genre_scores_gemma":[0.99787176,0.000652134,0.00032671928,0.00078729924,0.000009666802,0.000022699389,0.00018825788,0.0000033593542,0.00013813889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996516,0.0015437893,0.0005785098,0.0003224975,0.0007995955,0.0002396036],"domain_scores_gemma":[0.9833452,0.004520401,0.008179021,0.000490392,0.0017501949,0.0017147855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031517912,0.00009796096,0.0002309304,0.00065425434,0.0005485396,0.0008012326,0.00035846757,0.0006382609,0.0012844574],"category_scores_gemma":[0.011813661,0.00026659505,0.00028360175,0.00086923275,0.0005724287,0.00086301885,0.000623358,0.0007170495,0.00021309247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004346125,0.00007711302,0.9864892,0.000063445106,0.000028096678,0.00013263106,0.0038458658,0.000068614325,0.00028028153,0.000037023834,0.0010212323,0.00791301],"study_design_scores_gemma":[0.00001215205,0.00030395953,0.98318255,0.00014666036,0.000016986465,0.0007422321,0.012767125,0.00047852183,0.00016650937,0.000023559724,0.0021424764,0.00001732245],"about_ca_topic_score_codex":0.022687305,"about_ca_topic_score_gemma":0.032636493,"teacher_disagreement_score":0.022687305,"about_ca_system_score_codex":0.0011269437,"about_ca_system_score_gemma":0.0014655329,"threshold_uncertainty_score":0.045110524},"labels":[],"label_agreement":null},{"id":"W7110187874","doi":"10.1080/23995270.2025.2580913","title":"AIRLEAF <sup>®</sup> –a study of verducatib as a new kind of treatment for bronchiectasis: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Grifols; Vertex Pharmaceuticals; AstraZeneca; CSL Behring; Chiesi Farmaceutici; Sanofi; Deutsche Forschungsgemeinschaft; GlaxoSmithKline; Pfizer; Bundesministerium für Bildung und Forschung; Insmed; McGill University; Gilead Sciences; Boehringer Ingelheim","keywords":"Bronchiectasis; Exacerbation; Plain language; Placebo; Disease; Pill; Lung disease; Quality of life (healthcare)","score_opus":0.010421917389047939,"score_gpt":0.33273688081795516,"score_spread":0.3223149634289072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7110187874","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020847613,0.74512804,0.0016434374,0.13552836,0.036799327,0.0048810677,0.015386108,0.00033614496,0.03944989],"genre_scores_gemma":[0.07247771,0.53630376,0.0055278395,0.24216183,0.0619472,0.00725295,0.009909865,0.00031223954,0.06410655],"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9979765,0.0011075954,0.00038138495,0.000111780195,0.0003229828,0.00009971115],"domain_scores_gemma":[0.9897085,0.0065204585,0.0016314769,0.00019947177,0.001338851,0.0006012329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062867883,0.0007498022,0.0020398963,0.0005455615,0.00044892562,0.0029170825,0.0009885136,0.0024628981,0.03518908],"category_scores_gemma":[0.008986559,0.000431395,0.0024765169,0.0004988991,0.000527623,0.001354748,0.0006051666,0.0029157388,0.007434683],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050103694,0.0013485135,0.0013626044,0.065952346,0.0024307773,0.00073021196,0.00033158247,0.00037545493,0.003953535,0.003272614,0.51959974,0.35053897],"study_design_scores_gemma":[0.036544256,0.029964143,0.009205609,0.036400672,0.004783674,0.0007927689,0.00046275154,0.00039935735,0.0024638267,0.003419786,0.87534595,0.00021721577],"about_ca_topic_score_codex":0.0013458495,"about_ca_topic_score_gemma":0.0025652107,"teacher_disagreement_score":0.03518908,"about_ca_system_score_codex":0.0008291762,"about_ca_system_score_gemma":0.0017433745,"threshold_uncertainty_score":0.11771923},"labels":[],"label_agreement":null},{"id":"W7117318193","doi":"10.1080/23995270.2025.2607961","title":"The plight of rare diseases in Southern Africa: health and social services policy recommendations","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aga Khan Foundation","funders":"","keywords":"Social Welfare; Health services; Social policy; Government (linguistics); Health policy; Public health","score_opus":0.004839057227458282,"score_gpt":0.2559353968020466,"score_spread":0.2510963395745883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117318193","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017182546,0.0047646156,0.00052028085,0.9775109,0.0044486937,0.00026130793,0.00056054303,0.000098609955,0.0101168305],"genre_scores_gemma":[0.050888434,0.02183388,0.015555756,0.8772285,0.0063344454,0.002145822,0.0015116113,0.00008904523,0.024412405],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9909704,0.0034758106,0.0006273215,0.00040740916,0.0015586767,0.0029605099],"domain_scores_gemma":[0.9665502,0.011432068,0.0020442067,0.00064348325,0.0069193277,0.0124107655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016549684,0.0018723168,0.0010334123,0.0031955359,0.0041535036,0.007628896,0.0033607588,0.0236758,0.033997767],"category_scores_gemma":[0.038093705,0.00058990443,0.0027565619,0.0020032292,0.0033363472,0.008359055,0.008803833,0.012816084,0.0037068499],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001468871,0.00051474,0.005133674,0.002930443,0.00011523573,0.0016447508,0.0033483056,0.0016102734,0.001068736,0.05899879,0.83720344,0.08728474],"study_design_scores_gemma":[0.0003930524,0.00024462852,0.010154943,0.011019075,0.00023237179,0.00046477377,0.009856625,0.0011923601,0.0005339709,0.036966454,0.92877805,0.0001636406],"about_ca_topic_score_codex":0.077149585,"about_ca_topic_score_gemma":0.06447762,"teacher_disagreement_score":0.077149585,"about_ca_system_score_codex":0.0088992715,"about_ca_system_score_gemma":0.08489612,"threshold_uncertainty_score":0.15340102},"labels":[],"label_agreement":null}]}